Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | CEL | P19835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95364 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL3036894 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL207351 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831413 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL21831588 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL866938 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL867290 | 1.00 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1HPGDKDM5A | |
| SCHEMBL22524 | 0.97 | — | — | |
| SCHEMBL29156058 | 0.94 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1KDM5APHF8 | |
| SCHEMBL25313563 | 0.92 | SIGMAR1 (0.56) | CYP1A2SIGMAR1EPHX1KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3597670-B1 | WATER-SOLUBLE COMPOSITION, PRODUCTION METHOD FOR CURED PRODUCT THEREOF, AND CURED PRODUCT THEREOF, AND ACYL PHOSPHINATE | ADEKA CORP (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118103209-A | Composition for forming release layer, laminate, and method for producing laminate | 日产化学株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-113166554-B | xanthene compounds | 株式会社艾迪科 | 2023-12-12 | — | — | CN | disclosed |
| CN-110036343-B | Water-soluble composition, pattern forming agent, method for producing cured product using same, and cured product | 株式会社ADEKA | 2023-06-13 | — | — | CN | disclosed |
| US-11649334-B2 | Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate | ADEKA CORPORATION (JP) | 2023-05-16 | — | — | US | disclosed |
| WO-2023074171-A1 | RELEASE LAYER-FORMING COMPOSITION, LAMINATE, AND METHOD FOR MANUFACTURING LAMINATE | 日産化学株式会社 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023074169-A1 | PRIMER LAYER-FORMING COMPOSITION, LAMINATE, AND METHOD FOR DECOMPOSING LAMINATE | 日産化学株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-114072474-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-04-28 | — | — | CN | disclosed |
| CN-115836100-A | Polymerizable composition, cured product, and method for producing cured product | 株式会社艾迪科 | 2023-03-21 | — | — | CN | disclosed |
| WO-2010142779-A1 | ANTIFUNGAL 1,2,4-TRIAZOLYL DERIVATIVES HAVING A 5- SULFUR SUBSTITUENT | BASF SE (DE) | 2010-12-16 | — | — | WO | disclosed |
| US-20100204320-A1 | PHARMACEUTICALS FOR XEROSIS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-12 | — | — | US | disclosed |
| US-7737182-B2 | Pharmaceuticals for xerosis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7718701-B2 | Prostaglandin, e.g., 1R,2R,3R,5R)-5-halo-2-[(1E,3S)-3-cycloalkyl-3-hydroxy-1-propenyl]-3-hydroxycyclopentyl]-(5Z)-5-alkenoic acids; treating in particular, symptoms of atopic dermatitis | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1527781-B1 | ANTIPRURITIC AGENT | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20050192357-A1 | Pharmaceuticals for xerosis | Sato, Fumie | 2005-09-01 | — | — | US | disclosed |
| EP-1527781-A1 | ANTIPRURITIC AGENT | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-20050009917-A1 | Antipruritic agent | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009917-A1 | Antipruritic agent | HRH2, HRH4, HRH1 | CYP1A2 1723/4885SIGMAR1 220/4885EPHX1 312/4885 |
| US-20100204320-A1 | PHARMACEUTICALS FOR XEROSIS | PTGDR, PTGDR2, PTGIR | CYP1A2 899/4885SIGMAR1 797/4885EPHX1 841/4885 |
| US-20050192357-A1 | Pharmaceuticals for xerosis | PTGDR, PTGDR2, PTGIR | CYP1A2 993/4885SIGMAR1 694/4885EPHX1 881/4885 |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | F12, F10, PCNA | CYP1A2 356/4885SIGMAR1 2719/4885EPHX1 1588/4885 |
| US-11649334-B2 | Water-soluble composition, production method for cured product thereof, and cured product thereof, and acyl phosphinate | PHOSPHO1, ASS1, SGMS1 | CYP1A2 2508/4885SIGMAR1 2309/4885EPHX1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.